Biodesix Inc. (BDSX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so far this year.
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges
BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth offset workforce strains.
Biodesix Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Drew Phillips Fortitude Family Office LLC | 171 | $1,291 | $3,452.49 | $2,161.49 | 167.43% |
 Kevin Roan Stempoint Capita LLP | 70,004 | $1.02M | $1.43M | $410,923.48 | 40.48% |
Biodesix Inc. (BDSX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biodesix Inc. ever had a stock split?
Biodesix Inc. Profile
| Professional Services Industry | Industrials Sector | Scott Hutton CEO | NASDAQ (NMS) Exchange | 09075X207 CUSIP |
| US Country | 334 Employees | - Last Dividend | 15 Sep 2025 Last Split | 28 Oct 2020 IPO Date |
Overview
Biodesix, Inc. is recognized as a pioneering diagnostic solutions company based in the United States, focusing specifically on data-driven diagnostics. Initially named Elston Technologies, Inc., the company underwent a rebranding to Biodesix, Inc. in 2006 and was officially incorporated a year earlier, in 2005. With its headquarters in Louisville, Colorado, Biodesix stands at the forefront of providing comprehensive diagnostic and prognostic solutions, primarily targeting lung cancer through innovative blood-based lung tests. Moreover, it extends its expertise to managing the challenges of the COVID-19 pandemic by offering accurate testing solutions through strategic partnerships. In its commitment to advancing personalized medicine, Biodesix also engages in the discovery, development, and commercialization of companion diagnostics, catering both to direct patient care and to the biopharmaceutical sector for clinical research and trial testing services.
Products and Services
- Nodify XL2 and Nodify CDT tests: These are integral components of the Nodify Lung Nodule Risk Assessment testing strategy, designed to evaluate the risk of lung cancer. They aid physicians in reclassifying the risk of malignancy in patients presenting with suspicious lung nodules, focusing on identifying the most appropriate treatment pathway.
- GeneStrat ddPCR and NGS, and VeriStrat tests: Employed in the diagnosis and treatment decisions of lung cancer, these tests measure the presence of mutations within tumors and assess the state of the patient's immune system. This information is vital for establishing the patient's prognosis and for guiding treatment decisions.
- Bio-Rad SARS-CoV-2 ddPCR: Developed through a partnership with Bio-Rad Laboratories, Inc., this is a COVID-19 diagnostic test offered under the Biodesix WorkSafe testing program. It's known for its precision in detecting SARS-CoV-2, contributing to the control of the pandemic's spread.
- Platelia SARS-CoV-2 Total Ab test: Also a fruit of the partnership with Bio-Rad Laboratories, Inc., this antibody test detects a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. It adds a crucial layer to understanding the pandemic's impact and individual exposure levels.
- Diagnostic and Clinical Research Services: Beyond individual diagnostics, Biodesix offers services to biopharmaceutical companies. These include clinical trial testing services and the discovery, development, and commercialization of companion diagnostics, playing a significant role in the advancement of personalized medicine.
